Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2599023 (DTX201) dose-escalation study in adults with severe hemophilia A
NL-OMON60287Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2019
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peboctocogene camaparvovec in hemophilia A, sponsored by Bayer. Primary endpoint: Safety and tolerability. Started Mar 2019; status: completed.
02
Drugs
peboctocogene camaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON60287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60287.